1. Academic Validation
  2. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect

Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect

  • J Clin Invest. 2007 Nov;117(11):3236-47. doi: 10.1172/JCI32461.
Erica Salvati 1 Carlo Leonetti Angela Rizzo Marco Scarsella Marcella Mottolese Rossella Galati Isabella Sperduti Malcolm F G Stevens Maurizio D'Incalci Maria Blasco Giovanna Chiorino Serge Bauwens Béatrice Horard Eric Gilson Antonella Stoppacciaro Gabriella Zupi Annamaria Biroccio
Affiliations

Affiliation

  • 1 Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy.
Abstract

Functional telomeres are required for the replicability of Cancer cells. The G-rich strand of telomeric DNA can fold into a 4-stranded structure known as the G-quadruplex (G4), whose stabilization alters telomere function limiting Cancer cell growth. Therefore, the G4 ligand RHPS4 may possess antitumor activity. Here, we show that RHPS4 triggers a rapid and potent DNA damage response at telomeres in human transformed fibroblasts and melanoma cells, characterized by the formation of several telomeric foci containing phosphorylated DNA damage response factors gamma-H2AX, RAD17, and 53BP1. This was dependent on DNA repair Enzyme ATR, correlated with delocalization of the protective telomeric DNA-binding protein POT1, and was antagonized by overexpression of POT1 or TRF2. In mice, RHPS4 exerted its antitumor effect on xenografts of human tumor cells of different histotype by telomere injury and tumor cell Apoptosis. Tumor inhibition was accompanied by a strong DNA damage response, and tumors overexpressing POT1 or TRF2 were resistant to RHPS4 treatment. These data provide evidence that RHPS4 is a telomere damage inducer and that telomere disruption selectively triggered in malignant cells results in a high therapeutic index in mice. They also define a functional link between telomere damage and antitumor activity and reveal the key role of telomere-protective factors TRF2 and POT1 in response to this anti-telomere strategy.

Figures
Products